Can I Take Ashwagandha with Leqvio (Inclisiran)? A Women's Health Guide

What Are We Actually Asking Here?

You take ashwagandha for stress, sleep, or energy. Your cardiologist or internist just prescribed Leqvio for high LDL. You want to know whether the two can coexist safely. This is a completely reasonable question, and the honest answer is that the evidence is thinner than either you or your clinician might hope.

Inclisiran (brand name Leqvio) is a small-interfering RNA (siRNA) therapy that silences the gene encoding PCSK9 in the liver. Lower PCSK9 means more LDL receptors survive on liver cell surfaces, which pulls more LDL out of circulation. In the ORION-10 trial, inclisiran reduced LDL cholesterol by 52% from baseline at 510 days in patients with atherosclerotic cardiovascular disease.

Ashwagandha (Withania somnifera) is an adaptogenic root used in Ayurvedic medicine. Its active constituents, primarily withanolides, affect the hypothalamic-pituitary-adrenal (HPA) axis, the hypothalamic-pituitary-thyroid (HPT) axis, and steroidogenesis. That hormonal reach is exactly why the question matters.

How Inclisiran Works (and Why the Liver Matters)

The PCSK9-Silencing Mechanism

Inclisiran is injected subcutaneously by a healthcare provider. It is taken up by hepatocytes via the asialoglycoprotein receptor and packaged into RISC (RNA-induced silencing complex), which degrades PCSK9 messenger RNA before it can be translated into protein. The drug does not enter the systemic circulation in meaningful concentrations after hepatic uptake, and it is not metabolized by CYP450 enzymes. That last point is clinically important: most herb-drug interactions at the CYP level do not apply here.

What Inclisiran Is Prescribed For in Women

Inclisiran carries FDA approval for adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), alongside diet and maximally tolerated statins. Women are prescribed inclisiran in the same situations as men, but there are sex-specific patterns worth naming:

• Women with HeFH are diagnosed later and undertreated compared to men, even though their lifetime cardiovascular risk is substantial.
• LDL rises sharply in perimenopause and post-menopause, sometimes making lipid-lowering therapy necessary for the first time in a woman's 40s or 50s.
• Women with PCOS have higher rates of dyslipidemia and elevated cardiovascular risk that may justify earlier or more aggressive LDL lowering.

What Ashwagandha Actually Does Physiologically

Cortisol and the HPA Axis

Ashwagandha's best-documented action is HPA-axis modulation. A 2019 randomized controlled trial (n=60) found that 240 mg/day of standardized ashwagandha root extract reduced serum cortisol by 23% versus placebo over 60 days. Cortisol reduction sounds straightforwardly good, but cortisol influences glucose homeostasis, blood pressure, and immune response. In women with adrenal insufficiency or those on corticosteroids, this effect can be clinically consequential.

Thyroid Hormone Effects

Ashwagandha modestly raises thyroid hormones. A 2018 pilot RCT (n=50) in patients with subclinical hypothyroidism showed that 600 mg/day of ashwagandha root extract significantly increased serum T3 and T4 and reduced TSH compared to placebo after 8 weeks. If you are already on levothyroxine, adding ashwagandha may push your thyroid levels above range. This is not an interaction with inclisiran directly, but it is a systemic effect your prescriber needs to know about.

Androgen and Lipid Effects

This is where the interaction gets more specifically relevant to inclisiran's job. Some trial data suggest ashwagandha may raise testosterone in men, but data in women is sparse. A 2023 RCT in women (n=80) found improvements in sexual function and a modest reduction in stress without significant androgenic adverse events. Women with PCOS already have relative androgen excess, so even a small androgen-raising effect is worth monitoring.

On lipids specifically: a 2020 meta-analysis of ashwagandha RCTs found small but statistically significant reductions in total cholesterol (mean difference: -11.83 mg/dL) and triglycerides (-12.87 mg/dL). This means ashwagandha may modestly support the same lipid goals as inclisiran, which is pharmacodynamically additive rather than antagonistic. There is no evidence ashwagandha blunts inclisiran's LDL-lowering effect.

The Interaction Question: Pharmacokinetic vs. Pharmacodynamic

A useful framework for thinking about any supplement-drug pairing distinguishes two types of interaction:

Pharmacokinetic (PK) interactions change how a drug is absorbed, distributed, metabolized, or excreted. Because inclisiran bypasses CYP450 metabolism and is hepatically sequestered after subcutaneous delivery, the classic herb-drug PK interactions (think St. John's Wort and CYP3A4) do not apply. The FDA label lists no known PK drug interactions.

Pharmacodynamic (PD) interactions occur when two substances affect the same physiological pathway. This is the real concern with ashwagandha and inclisiran:

| Pathway | Inclisiran Effect | Ashwagandha Effect | Clinical Relevance | |---|---|---|---| | LDL-C reduction | Reduces by ~50% via PCSK9 silencing | Modestly reduces total-C and TG | Additive; unlikely harmful | | Thyroid hormones | No direct effect | May raise T3/T4, lower TSH | Risk if thyroid disease is present | | Cortisol | No direct effect | Reduces serum cortisol ~23% | Risk with adrenal disease or steroids | | Androgens | No direct effect | Uncertain in women; small studies | Monitor in PCOS | | Liver enzymes | Rare transaminase elevation reported | Rare hepatotoxicity cases reported | Monitor LFTs if both used long-term |

No published study has directly examined inclisiran plus ashwagandha. This evidence gap is real. What follows is reasoned clinical extrapolation, not direct trial data.

Life-Stage Breakdown: How This Changes Across a Woman's Life

Reproductive Years and Trying to Conceive

If you are in your 20s or 30s, taking inclisiran is uncommon unless you have familial hypercholesterolemia. If you are in this life stage and have HeFH, the pregnancy and contraception requirements for inclisiran (see dedicated section below) override almost every other consideration.

Ashwagandha's androgen-modulating effects are relevant if you have PCOS and are trying to conceive. Some practitioners use it as an adjunct for stress and ovarian function, but the evidence in TTC women is not strong enough to make a firm recommendation, and the thyroid-raising effect may interfere with fertility monitoring.

Perimenopause

This is where inclisiran prescriptions in women are most likely to begin. The average LDL increase in the menopausal transition is 10-14 mg/dL, and many women cross a treatment threshold for the first time in their late 40s or early 50s. Stress, sleep disruption, and fatigue in perimenopause also make ashwagandha appealing.

The cortisol-lowering effect of ashwagandha may genuinely help perimenopausal HPA-axis dysregulation. The thyroid effect matters more in this life stage because subclinical hypothyroidism prevalence rises with age and is more common in women. Get a TSH and free T4 at baseline if you plan to use both.

Post-Menopause

Post-menopause is the most common life stage for cardiovascular risk management and, therefore, for inclisiran. Ashwagandha continues to be used for sleep, cognition, and energy. The same monitoring parameters apply. Liver enzymes are worth checking annually in post-menopausal women using both agents long-term, since both carry rare reports of hepatocellular effects.

PCOS and Inclisiran: A Specific Note

Women with PCOS have a two- to threefold higher prevalence of dyslipidemia compared to women without PCOS. If you have PCOS and dyslipidemia severe enough to warrant inclisiran, you are likely also managing insulin resistance, elevated androgens, and possibly thyroid disease, all of which ashwagandha touches.

The pharmacodynamic overlap is not alarming, but it creates a monitoring burden. Your lipid panel, thyroid function, and liver enzymes should be tracked when you are on inclisiran regardless; adding ashwagandha means those same labs become more informationally valuable. Check them every 6 months for the first year if you combine these agents.

Pregnancy, Lactation, and Contraception

Inclisiran is contraindicated in pregnancy. The FDA label states that animal studies showed fetal harm at exposures below the human clinical dose, and no adequate human data exist. Because inclisiran is administered only twice yearly, a missed dose in early pregnancy would still represent recent drug exposure.

Women of reproductive potential prescribed inclisiran should use effective contraception throughout treatment and for a period following discontinuation. Discuss the specific duration with your prescriber; the label does not define a washout window, but the half-life of effect is approximately 6 months given the dosing interval.

Ashwagandha is also contraindicated in pregnancy. One case series and animal studies associate high-dose ashwagandha with uterotonic activity and possible early pregnancy loss. If you become pregnant while taking either agent, stop both and contact your provider the same day.

Lactation: Inclisiran transfer into human breast milk has not been studied. The FDA label advises against use during breastfeeding. Ashwagandha transfer into breast milk is not well characterized either. Neither agent has established safety data in lactation. Both should be avoided while breastfeeding.

Contraception requirement: Any woman of reproductive potential on inclisiran should use a reliable non-hormonal or hormonal contraceptive method (your choice, in consultation with your provider) for the duration of treatment. This is not optional. The drug's twice-yearly injection schedule creates a long biologically active window.

What to Tell Your Clinician

Your prescriber needs to know about every supplement you take, including ashwagandha. Many women assume "natural" means outside the scope of a medical conversation. It is not.

Specifically, before combining ashwagandha with inclisiran, your prescriber should order:

• A baseline TSH and free T4 (to catch subclinical thyroid disease before ashwagandha raises thyroid hormones further)
• A baseline comprehensive metabolic panel (to check liver enzymes given the rare hepatotoxicity signal with ashwagandha)
• A fasting lipid panel timed to your inclisiran injection schedule (typically at 3 months post-injection)

If your TSH is already low-normal or you have hyperthyroid symptoms, ashwagandha is not an appropriate choice alongside any thyroid-active medication, and the decision becomes more complex even without inclisiran in the picture.

Who This Combination Is Likely Fine For vs. Who Should Be Cautious

Probably Lower Risk

• Post-menopausal women with no thyroid disease, normal liver enzymes, and well-controlled LDL on inclisiran
• Women using ashwagandha at standard doses (300-600 mg/day of root extract) for 8-12 weeks rather than indefinitely
• Women who have disclosed use to their prescriber and have baseline labs checked

Requires Active Monitoring

• Women with PCOS (androgen and metabolic overlap)
• Women with subclinical or overt thyroid disease
• Women on levothyroxine (ashwagandha may alter your thyroid levels enough to change your dose)
• Perimenopausal women with fluctuating HPA-axis function

Should Not Combine Without Specialist Input

• Women with adrenal insufficiency or on chronic corticosteroids
• Women with elevated liver enzymes at baseline
• Women who are pregnant or planning pregnancy in the next 6-12 months

Practical Guidance If You Are Already Taking Both

If you started ashwagandha before your inclisiran prescription, or added it afterward without telling your cardiologist, do not stop either abruptly without guidance. Stopping inclisiran mid-course undermines the sustained PCSK9 silencing that drives its efficacy. Stopping ashwagandha abruptly is unlikely to cause physiological rebound at standard doses but should still be done in communication with your prescriber.

The right step is to schedule a brief telehealth or in-office visit, bring the ashwagandha supplement label, and ask for the baseline labs described above. A cardiologist who is not familiar with ashwagandha's thyroid effects may benefit from seeing the 2018 RCT data you can share from this article.

"Women in particular are less likely to volunteer information about supplement use to their cardiovascular care team, partly because those conversations have historically felt unwelcome," notes the ACOG Committee Opinion on Dietary Supplements. Creating space for that conversation is part of what good women's cardiovascular care looks like.

The Evidence Gap: What We Do Not Know

Women have been underrepresented in cardiovascular drug trials for decades. The ORION trial program that led to inclisiran's approval included women, but sex-stratified interaction data with supplements has not been published. Ashwagandha research in women specifically is limited; most published RCTs included predominantly male participants or mixed populations without sex-stratified outcomes.

What this means for you: clinical guidance on this combination rests on mechanism-based reasoning and individual physiological parameters, not on a definitive trial showing it is safe or unsafe. That is an honest limitation, and any clinician who tells you otherwise is overstating the evidence.

The most specific piece of caution worth repeating: ashwagandha's thyroid-raising effect in women with subclinical hypothyroidism is the most clinically meaningful pharmacodynamic consideration in this pairing. Inclisiran does not fix or worsen thyroid function, but if ashwagandha pushes you from subclinical to overt hyperthyroidism, that will affect your cardiovascular risk profile in exactly the direction inclisiran is trying to improve.

Your next step: check your most recent TSH. If it was more than 12 months ago, ask for a repeat before adding or continuing ashwagandha.